One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial

By sjmartinez • October 23, 2023

Jilg N, Chew KW, Giganti MJ, Daar ES, Wohl DA, Javan AC, Kantor A, Moser C, Coombs RW, Neytman G, Hoover K, Jana A, Hart PA, Greninger AL, Szurgot B, Eron JJ, Currier JS, Hughes MD, Smith DM, Li JZ; ACTIV-2/A5401 Study Team. One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial. Clin Infect Dis. 2023 Oct 5;77(7):941-949. doi: 10.1093/cid/ciad342. PMID: 37279602; PMCID: PMC10552586.

Tags: camostat, covid-19, Harbor UCLA, Infectious Diseases, outpatient, phase, Publications, SARS-CoV-2

Semaglutide and kidney function: direct kidney protection or an artifact?

Ayoub I, Wong G, Glassock RJ. Semaglutide and kidney function: direct kidney protection or an artifact? Kidney Int. 2024 Nov 18:S0085-2538(24)00793-2. doi: 10.1016/j.kint.2024.11.003. Epub ahead[...]

Moving on from clinical animal-derived surfactants to peptide-based synthetic pulmonary surfactant

Walther FJ, Waring AJ. Moving on from clinical animal-derived surfactants to peptide-based synthetic pulmonary surfactant. Am J Physiol Lung Cell Mol Physiol. 2024 Dec 1;327(6):L883-L889.[...]

Influence of Thyroglobulin Autoantibodies on Thyroglobulin Levels Measured by Different Methodologies: IMA, LC-MS/MS, and RIA

Petrovic I, LoPresti J, Fatemi S, Gianoukakis A, Burman K, Gomez-Lima CJ, Nguyen CT, Spencer CA. Influence of Thyroglobulin Autoantibodies on Thyroglobulin Levels Measured by[...]